You have no items in your cart.
Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in combination with Keytruda (pembrolizumab) and chemotherapy. The study is enrolling adults with triple-negative breast cancer (TNBC) — cancers not driven by the hormones progesterone or estrogen, or by the protein HER2 — according to the therapy’s developer, Brooklyn ImmunoTherapeutics. Already underway at the Providence Cancer Institute, in Portland, Ore., the trial (NCT04373031) is expected to enroll…